CN112639474A - 血清生物标志物 - Google Patents

血清生物标志物 Download PDF

Info

Publication number
CN112639474A
CN112639474A CN201980045744.6A CN201980045744A CN112639474A CN 112639474 A CN112639474 A CN 112639474A CN 201980045744 A CN201980045744 A CN 201980045744A CN 112639474 A CN112639474 A CN 112639474A
Authority
CN
China
Prior art keywords
subject
treatment
inhibiting
biomarkers
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980045744.6A
Other languages
English (en)
Chinese (zh)
Inventor
R.霍尔特
D.米克莱姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BerGenBio ASA
Original Assignee
BerGenBio ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807789.1A external-priority patent/GB201807789D0/en
Priority claimed from GBGB1816764.3A external-priority patent/GB201816764D0/en
Priority claimed from GBGB1817024.1A external-priority patent/GB201817024D0/en
Application filed by BerGenBio ASA filed Critical BerGenBio ASA
Publication of CN112639474A publication Critical patent/CN112639474A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
CN201980045744.6A 2018-05-14 2019-05-13 血清生物标志物 Pending CN112639474A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1807789.1 2018-05-14
GBGB1807789.1A GB201807789D0 (en) 2018-05-14 2018-05-14 Serum biomarkers
GBGB1816764.3A GB201816764D0 (en) 2018-10-15 2018-10-15 Serum biomarkers
GB1816764.3 2018-10-15
GBGB1817024.1A GB201817024D0 (en) 2018-10-19 2018-10-19 Serum biomarkers
GB1817024.1 2018-10-19
PCT/EP2019/062215 WO2019219612A1 (en) 2018-05-14 2019-05-13 Serum biomarkers

Publications (1)

Publication Number Publication Date
CN112639474A true CN112639474A (zh) 2021-04-09

Family

ID=66589527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045744.6A Pending CN112639474A (zh) 2018-05-14 2019-05-13 血清生物标志物

Country Status (5)

Country Link
US (1) US20210215697A1 (https=)
EP (1) EP3794352A1 (https=)
JP (1) JP2021523379A (https=)
CN (1) CN112639474A (https=)
WO (1) WO2019219612A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118359697A (zh) * 2024-04-29 2024-07-19 上海硅羿生物技术有限公司 β淀粉样蛋白40及β淀粉样蛋白42特异识别多肽及其应用
CN121186348A (zh) * 2025-11-25 2025-12-23 北京大学人民医院 瓜氨酸化内凝集素-1多肽在制备类风湿关节炎诊断产品中的应用
CN121186365A (zh) * 2025-11-25 2025-12-23 长兴固容生物科技有限公司 一种用于胰腺癌筛查、诊断的标志物组及其用途
CN121186360A (zh) * 2025-11-25 2025-12-23 长兴固容生物科技有限公司 一种用于乳腺癌筛查、诊断的标志物组及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004189D0 (en) * 2020-03-23 2020-05-06 Bergenbio As Combination therapy
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
WO2023059527A1 (en) * 2021-10-04 2023-04-13 Tintoria Piana, Inc. Diagnostic system and methods of using and manufacturing the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822844A (zh) * 2012-10-01 2015-08-05 米伦纽姆医药公司 预测对抑制剂的反应的生物标记物和方法以及其用途
WO2015193430A1 (en) * 2014-06-18 2015-12-23 Bergenbio As Anti-axl antibodies
WO2015193428A1 (en) * 2014-06-18 2015-12-23 Bergenbio As Anti-axl antibodies
WO2016097370A2 (en) * 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
WO2016166296A2 (en) * 2015-04-15 2016-10-20 Bergenbio As Humanized anti-axl antibodies
WO2017009261A1 (en) * 2015-07-10 2017-01-19 Bergenbio As Biomarkers for cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
CA2971763A1 (en) 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822844A (zh) * 2012-10-01 2015-08-05 米伦纽姆医药公司 预测对抑制剂的反应的生物标记物和方法以及其用途
WO2015193430A1 (en) * 2014-06-18 2015-12-23 Bergenbio As Anti-axl antibodies
WO2015193428A1 (en) * 2014-06-18 2015-12-23 Bergenbio As Anti-axl antibodies
WO2016097370A2 (en) * 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
WO2016166296A2 (en) * 2015-04-15 2016-10-20 Bergenbio As Humanized anti-axl antibodies
WO2017009261A1 (en) * 2015-07-10 2017-01-19 Bergenbio As Biomarkers for cancer

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118359697A (zh) * 2024-04-29 2024-07-19 上海硅羿生物技术有限公司 β淀粉样蛋白40及β淀粉样蛋白42特异识别多肽及其应用
CN121186348A (zh) * 2025-11-25 2025-12-23 北京大学人民医院 瓜氨酸化内凝集素-1多肽在制备类风湿关节炎诊断产品中的应用
CN121186365A (zh) * 2025-11-25 2025-12-23 长兴固容生物科技有限公司 一种用于胰腺癌筛查、诊断的标志物组及其用途
CN121186360A (zh) * 2025-11-25 2025-12-23 长兴固容生物科技有限公司 一种用于乳腺癌筛查、诊断的标志物组及其用途
CN121186348B (zh) * 2025-11-25 2026-02-24 北京大学人民医院 瓜氨酸化内凝集素-1多肽在制备类风湿关节炎诊断产品中的应用
CN121186360B (zh) * 2025-11-25 2026-04-14 长兴固容生物科技有限公司 一种用于乳腺癌筛查、诊断的标志物组及其用途

Also Published As

Publication number Publication date
US20210215697A1 (en) 2021-07-15
WO2019219612A1 (en) 2019-11-21
JP2021523379A (ja) 2021-09-02
EP3794352A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
CN112639474A (zh) 血清生物标志物
Veyssière et al. Circulating proteins as predictive and prognostic biomarkers in breast cancer
Debucquoy et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer
US9255927B2 (en) Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
CA2706994A1 (en) Use of eph-b4 and ephrin-a1 for predicting negative physiological response to the treatment with erythropoietin
Jiang et al. Identification of five serum protein markers for detection of ovarian cancer by antibody arrays
JP5224308B2 (ja) 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用
WO2015157557A1 (en) Methods of diagnosing pancreatic cancer and methods related thereto
EP3015864A1 (en) Biomarkers for the diagnosis and the response to treatment of pancreatic cancer
CA3206126A1 (en) Biomarkers for breast cancer detection
EP3080299B1 (en) Biomarkers of rapid progression in advanced non-small cell lung cancer
US20120201750A1 (en) Serum biomarkers for melanoma metastasis
JP5568807B2 (ja) プロテオミクス解析を用いたメラノーママーカーの同定
US20180274037A1 (en) Novel biomarkers for pancreatic diseases
Hjortebjerg et al. Pregnancy-associated plasma protein-A2 is associated with mortality in patients with lung cancer
HK40046705A (en) Serum biomarkers
KR102273171B1 (ko) 갑상선암 예후 예측용 바이오 마커
EP2895863B1 (en) New biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma
WO2021013891A1 (en) Methods for diagnosing cancer
WO2009150491A2 (en) Interferon epsilon (ifne1) as a marker for targeted cancer therapy
CN103713129B (zh) 分子标记物在甲状旁腺肿瘤诊断中的用途
CN116179707A (zh) 一种肾癌预后标记物及其应用
Škereňová et al. Gene expression analysis of immunomagnetically enriched circulating tumor cell fraction in castration-resistant prostate cancer
US20230357856A1 (en) Methods and compositions for prognosing glioblastoma or breast cancer
KR102177269B1 (ko) 뇌종양 진단 또는 예후 예측용 바이오마커 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046705

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210409